By Henry Ehrlich
KALÉO, parent company of Auvi-Q, has announced that the auto injector will return to the market in February. As these things go, consumer terms seem exceptionally generous and thoughtful:
KALÉO ANNOUNCES U.S. AVAILABILITY AND PRICING TO PATIENTS OF AUVI-Q® (Epinephrine Injection, USP) AUTO-INJECTOR, FOR LIFE-THREATENING ALLERGIC REACTIONS
AUVI-Q will be available by prescription nationwide on February 14, 2017.
Kaléo launches AUVI-Q AffordAbility, a first-of-its-kind access program and commitment for AUVI-Q:
— More than 200 million Americans with commercial insurance, including those with high-deductible plans, will be able to obtain AUVI-Q for $0 out-of-pocket.
–AUVI-Q will be available free of charge to patients with a household income of less than $100,000 who do not have government or commercial insurance.
–The cash price for AUVI-Q is $360, and will be available to those patients without government or commercial insurance.